SCHEMBL6763509

SCHEMBL6763509

O=C(NCCN1CCOCC1)c1ccc(Oc2nn(Cc3ccccc3)c3ccccc23)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 3/20 0.45
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
CD274 Q9NZQ7 1/20 0.44
PIK3CA P42336 1/20 0.44
MDM4 O15151 1/20 0.44
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ABCB1 P08183 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766823 0.83 PTGER4 (0.46) SMN1; SMN2KDM4EMAPTL3MBTL1MAPK1
SCHEMBL6762222 0.81 KDM4E (0.56) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL6762770 0.79 CNR1 (0.54) SMN1; SMN2KDM4EMAPTMAPK1ALDH1A1
SCHEMBL6762976 0.79 PTGER4 (0.43) SMN1; SMN2KDM4E
SCHEMBL6760260 0.77 CNR1 (0.50) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL24273601 0.77 ABCB1 (0.65) PARP1KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL6762508 0.73 CNR1 (0.41) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL6762652 0.72 SLC16A3 (0.41) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL14584165 0.71 MEN1 (0.57) PARP1KMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL6764379 0.71 PDE5A (0.62) SMN1; SMN2KDM4EMAPTMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US claimed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO claimed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 PARP1 3004/4885KMT2A 4490/4885MEN1 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.